View Older Stories View More Recent Stories

Nov 3, 2021 07:30AM BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Canavan Disease
Oct 29, 2021 07:31AM BridgeBio Pharma Inc. (BBIO) Collaborates with Columbia University and Mount Sinai to Develop Potential Therapies for Genetic Diseases and Cancers
Oct 29, 2021 07:30AM BridgeBio Pharma Announces Collaborations with Columbia University and Mount Sinai to Develop Potential Therapies for Genetic Diseases and Cancers
Oct 12, 2021 07:35AM BridgeBio Pharma (BBIO) Announces Progress in its KRAS Portfolio, New Gene Therapy Programs, and Updates on Advancements Across its R&D Pipeline
Oct 12, 2021 07:30AM BridgeBio Pharma Announces Progress in its KRAS Portfolio, New Gene Therapy Programs, and Updates on Advancements Across its R&D Pipeline Targeting Genetic Diseases and Cancers
Oct 7, 2021 09:00AM BridgeBio Pharma Announces First Publication of Preclinical Data for its Potentially Best-in-Class SHP2 Inhibitor Designed for Treatment of Resistant Cancer, Showing Response in Established Non-small
Oct 6, 2021 07:30AM BridgeBio Pharma to Host Virtual R&D Day on October 12, 2021
Oct 1, 2021 05:00PM BridgeBio Pharma Announces Updated Phase 2B Data for Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1) Demonstrating Blood and Urine Calcium Normalization in Trial Participants
Sep 29, 2021 07:33AM Helsinn Group and BridgeBio Pharma’s (BBIO) Affiliate QED Therapeutics Announce Health Canada Conditional Approval of TRUSELTIQ for Patients with Cholangiocarcinoma
Sep 29, 2021 07:30AM Helsinn Group and BridgeBio Pharma’s Affiliate QED Therapeutics Announce Health Canada Conditional Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma
Sep 15, 2021 07:30AM BridgeBio Pharma (BBIO) Receives FDA Fast Track Designation for Investigational Therapy for Treatment of Limb-girdle Muscular Dystrophy Type 2i
Sep 15, 2021 07:30AM BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Therapy for the Treatment of Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)
Jun 1, 2021 07:00AM BridgeBio Pharma’s Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma
May 28, 2021 02:33PM BridgeBio Pharma (BBIO) Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ for Patients with Cholangiocarcinoma
May 28, 2021 02:30PM BridgeBio Pharma’s Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma
May 28, 2021 02:30PM BridgeBio Pharma’s Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma
Mar 31, 2021 07:34AM BridgeBio Pharma's (BBIO) Affiliate QED Therapeutics and Helsinn Group Announce Strategic Collaboration to Co-Develop and Commercialize Infigratinib in Oncology
Mar 31, 2021 07:30AM BridgeBio Pharma’s Affiliate QED Therapeutics and Helsinn Group Announce Strategic Collaboration to Co-Develop and Commercialize Infigratinib in Oncology
Mar 31, 2021 07:30AM BridgeBio Pharma’s Affiliate QED Therapeutics and Helsinn Group Announce Strategic Collaboration to Co-Develop and Commercialize Infigratinib in Oncology
Mar 31, 2021 07:30AM BridgeBio Pharma’s Affiliate QED Therapeutics and Helsinn Group Announce Strategic Collaboration to Co-Develop and Commercialize Infigratinib in Oncology
Dec 23, 2020 07:34AM UCSF and BridgeBio Pharma (BBIO) Collaborate to Accelerate the Development of Therapies for Genetic Diseases
Dec 23, 2020 07:30AM UCSF and BridgeBio Pharma Collaborate to Accelerate the Development of Therapies for Genetic Diseases
Dec 23, 2020 07:30AM UCSF and BridgeBio Pharma Collaborate to Accelerate the Development of Therapies for Genetic Diseases
Jul 28, 2020 07:35AM BridgeBio Pharma Inc. (BBIO), Ivy Brain Tumor Center Report First Patient Dosing in Investigator-Initiated Phase 0/2 Clinical Trial of Infigratinib in Recurrent Glioblastoma
Jul 28, 2020 07:30AM Ivy Brain Tumor Center and BridgeBio Pharma’s QED Therapeutics Announce Dosing of First Patient in Investigator-Initiated Phase 0/2 Clinical Trial of Infigratinib in Recurrent Glioblastoma
Jul 28, 2020 07:30AM Ivy Brain Tumor Center and BridgeBio Pharma’s QED Therapeutics Announce Dosing of First Patient in Investigator-Initiated Phase 0/2 Clinical Trial of Infigratinib in Recurrent Glioblastoma
Sep 24, 2019 07:00AM Ivy Brain Tumor Center and BridgeBio Subsidiary QED Therapeutics Announce Collaboration to Advance Cancer Research and Treatment Options
Sep 24, 2019 07:00AM Ivy Brain Tumor Center and BridgeBio Subsidiary QED Therapeutics Announce Collaboration to Advance Cancer Research and Treatment Options
View More Recent Stories View Older Stories